Determinants of glycaemic control in a practice setting: The role of weight loss and treatment adherence (The DELTA Study)

International Journal of Clinical Practice

Volumn 68, Issue 11, 2014, Pages 1309-1317

  McAdam Marx, C ^a   Bellows, B K ^a   Unni, S ^a   Mukherjee, J ^b   Wygant, G ^b   Iloeje, U ^b   Liberman, J N ^c   Ye, X ^a   Bloom, F J ^d   Brixner, D I ^a  

^a UNIVERSITY OF UTAH   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PRAMLINTIDE; SULFONYLUREA; GLUCAGON LIKE PEPTIDE 1; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COUNSELING; TREATMENT DURATION; UNITED STATES; WEIGHT CHANGE; WEIGHT REDUCTION; AGED; DIABETES MELLITUS, TYPE 2; DIET THERAPY; GLYCEMIC INDEX;

ADULT; AGED; BODY WEIGHT; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLYCEMIC INDEX; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; WEIGHT LOSS;

EID: 84916602535     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12502     Document Type: Article

References (41)

1. Niswender K,. Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay. Diabetes Obes Metab 2010; 12 (4): 267-87.
2. Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA,. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract 2011; 93 (Suppl. 1): S52-9.
3. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36 (4): 1033-46.
5. Zhang Y, Hu G, Yuan Z, Chen L,. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 2012; 7 (8): e42551.
6. Flint AJ, Hu FB, Glynn RJ, et al. Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring) 2010; 18 (2): 377-83.
7. Anderson JW, Kendall CW, Jenkins DJ,. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22 (5): 331-9.
8. Schwartz SS, Kohl BA,. Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. Mayo Clin Proc 2010; 85 (12 Suppl.): S15-26.
9. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15 (6): 540-59.
10. Ross SA, Dzida G, Vora J, Khunti K, Kaiser M, Ligthelm RJ,. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin 2011; 27 (7): 1431-8.
11. Chaudhry ZW, Gannon MC, Nuttall FQ,. Stability of body weight in type 2 diabetes. Diabetes Care 2006; 29 (3): 493-7.
12. Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008; 31 (10): 1960-5.
13. McAdam-Marx C, Mukherjee J, Bellows BK, et al. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data, 2014. http://dx.doi.org/10.1016/j.diabres.2013.12.038 (accessed July 29, 2013).
14. Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007; 30 (4): 807-12.
15. Chen CC, Tseng CH, Cheng SH,. Continuity of care, medication adherence, and health care outcomes among patients with newly diagnosed type 2 diabetes: a longitudinal analysis. Med Care 2013; 51 (3): 231-7.
16. Kim MY, Suh S, Jin SM, et al. Education as prescription for patients with type 2 diabetes mellitus: compliance and efficacy in clinical practice. Diabetes Metab J 2012; 36 (6): 452-9.
17. Nagrebetsky A, Griffin S, Kinmonth AL, Sutton S, Craven A, Farmer A,. Predictors of suboptimal glycaemic control in type 2 diabetes patients: the role of medication adherence and body mass index in the relationship between glycaemia and age. Diabetes Res Clin Pract 2012; 96 (2): 119-28.
18. Borgsteede SD, Westerman MJ, Kok IL, Meeuse JC, de Vries TP, Hugtenburg JG,. Factors related to high and low levels of drug adherence according to patients with type 2 diabetes. Int J Clin Pharm 2011; 33 (5): 779-87.
19. French DP, Wade AN, Farmer AJ,. Predicting self-care behaviours of patients with type 2 diabetes: the importance of beliefs about behaviour, not just beliefs about illness. J Psychosom Res 2013; 74 (4): 327-33.
20. Weber V, Bloom F, Pierdon S, Wood C,. Employing the electronic health record to improve diabetes care: a multifaceted intervention in an integrated delivery system. J Gen Intern Med 2008; 23 (4): 379-82.
21. Bloom FJ, Graf T, Anderer T, Stewart WF,. Redesign of a diabetes system of care using an all-or-none diabetes bundle to build teamwork and improve intermediate outcomes. Diabetes Spectr 2010; 23 (3): 165-9.
22. Horne R, Weinman J,. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47 (6): 555-67.
23. Farmer A, Kinmonth AL, Sutton S,. Measuring beliefs about taking hypoglycaemic medication among people with type 2 diabetes. Diabet Med 2006; 23 (3): 265-70.
24. Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28 (6): 441-6.
25. Davidson MB, Peters AL,. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102 (1): 99-110.
26. Jakicic JM, Otto AD, Lang W, et al. The effect of physical activity on 18-month weight change in overweight adults. Obesity (Silver Spring) 2011; 19 (1): 100-9.
27. Stevens J, Truesdale KP, McClain JE, Cai J,. The definition of weight maintenance. Int J Obes (Lond) 2006; 30 (3): 391-9.
28. McAdam-Marx C, Mukherjee J, Bellows BK, et al. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Clin Pract 2014; 103 (3): 402-11.
29. Gialamas A, Yelland LN, Ryan P, et al. Does point-of-care testing lead to the same or better adherence to medication? A randomised controlled trial: the PoCT in General Practice Trial. Med J Australia 2009; 191 (9): 487-91.
30. Kline RB,. Core SEM Techniques and Software. In:, Kenny DA, ed. Principles and Practice of Structural Equation Modeling, 2nd edn. New York, NY: Guilford Press, 2005: page 63-90.
31. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 (6): 1364-79.
32. Redmon JB, Bertoni AG, Connelly S, et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2010; 33 (6): 1153-8.
33. Wing RR,. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170 (17): 1566-75.
34. Briesacher BA, Andrade SE, Fouayzi H, Chan KA,. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28 (4): 437-43.
35. World Health Organization. Adherence to long-term therapies: evidence for action, 2003. http://www.who.int/chp/knowledge/publications/adherence-introduction.pdf (accessed July 29, 2013)
36. Garfield S, Clifford S, Eliasson L, Barber N, Willson A,. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol 2011; 11: 149.
37. National Institute for Health and Clinical Excellence. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence, 2009. http://www.nice.org.uk/nicemedia/live/11766/43042/43042.pdf.(accessed July 29, 2013)
38. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36 (Suppl. 1): S11-66.
39. McAdam-Marx C, Bellows BK, Wygant G, et al. Association of >5% weight loss and self-reported adherence with 6-month glycemic control in type 2 diabetes mellitus (T2DM): the DELTA Study. Diabetes 2013; 62 (Suppl. 1): A217-364.
40. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB,. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31 (1): 81-6.
41. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB,. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006; 29 (3): 504-9.